During this phase, early pharmacokinetic and safety evaluations of promising compounds are conducted through in vitro and in vivo studies, transforming initial screening ”hits” into optimized “lead” candidates.
By narrowing down candidates early, hit-to-lead minimizes costly failures in later stages. It bridges the gap between high-throughput screening and lead optimization, ensuring only the most viable compounds progress.
Every project is customized to fit client objectives: from rapid hit expansion campaigns to comprehensive lead optimization strategies. Our team’s expertise in medicinal chemistry and pharmacology allows us to efficiently prioritize the most promising compounds for progression into preclinical studies.
Ultimately, our Hit-to-Lead service provides the foundation for successful lead optimization, helping clients advance confidently toward candidate selection and clinical development.
